<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 29 Mar 2021 07:21:55 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>mRNA疫苗技术创新</title><link>https://mp.weixin.qq.com/s/UmCVHB7wTN_Df54o3BiRsQ</link><description></description><content:encoded><![CDATA[mRNA疫苗技术创新]]></content:encoded><pubDate>Mon, 29 Mar 2021 06:29:12 +0800</pubDate></item><item><title>全球第五款上市的CAR-T药物：靶向BCMA</title><link>https://mp.weixin.qq.com/s/Bnz39oxrQ4dz64xTEniN7w</link><description></description><content:encoded><![CDATA[全球第五款上市的CAR-T药物：靶向BCMA]]></content:encoded><pubDate>Sun, 28 Mar 2021 06:44:05 +0800</pubDate></item><item><title>肿瘤mRNA疫苗的临床研究进展</title><link>https://mp.weixin.qq.com/s/Hxfak48pEWJ2LKEghnbW_g</link><description></description><content:encoded><![CDATA[肿瘤mRNA疫苗的临床研究进展]]></content:encoded><pubDate>Sat, 27 Mar 2021 06:35:19 +0800</pubDate></item><item><title>LAG-3抗体项目迎来重大利好</title><link>https://mp.weixin.qq.com/s/rjxOioRiJKki3sA4bqRUEg</link><description></description><content:encoded><![CDATA[LAG-3抗体项目迎来重大利好]]></content:encoded><pubDate>Fri, 26 Mar 2021 06:11:55 +0800</pubDate></item><item><title>BiG年会 | 9位主席集结，寻找下一个创药蓝海！</title><link>https://mp.weixin.qq.com/s/S-TJxLxFy9jFd45rsijoQw</link><description></description><content:encoded><![CDATA[BiG年会 | 9位主席集结，寻找下一个创药蓝海！]]></content:encoded><pubDate>Thu, 25 Mar 2021 06:27:56 +0800</pubDate></item><item><title>溶瘤病毒概述（一）</title><link>https://mp.weixin.qq.com/s/HiQT2jkUBKV7qY35OciUjA</link><description></description><content:encoded><![CDATA[溶瘤病毒概述（一）]]></content:encoded><pubDate>Thu, 25 Mar 2021 06:27:56 +0800</pubDate></item><item><title>溶瘤病毒概述（二）</title><link>https://mp.weixin.qq.com/s/G8EAZSw0qGPAGJmgB6KxQA</link><description></description><content:encoded><![CDATA[溶瘤病毒概述（二）]]></content:encoded><pubDate>Thu, 25 Mar 2021 06:27:56 +0800</pubDate></item><item><title>BiG春季聚会 | ADC热潮下的临床冷思考！</title><link>https://mp.weixin.qq.com/s/HWe0-MRzoyEiv-KVavY_jw</link><description></description><content:encoded><![CDATA[BiG春季聚会 | ADC热潮下的临床冷思考！]]></content:encoded><pubDate>Wed, 24 Mar 2021 06:43:53 +0800</pubDate></item><item><title>人人学懂免疫学：第二十一期</title><link>https://mp.weixin.qq.com/s/SBQQtPYOy9w-uoepyk_HNA</link><description></description><content:encoded><![CDATA[人人学懂免疫学：第二十一期]]></content:encoded><pubDate>Wed, 24 Mar 2021 06:43:53 +0800</pubDate></item><item><title>中国生物医药BD机会与挑战</title><link>https://mp.weixin.qq.com/s/dYKbxnJ941wFasnGcq4n5g</link><description></description><content:encoded><![CDATA[中国生物医药BD机会与挑战]]></content:encoded><pubDate>Tue, 23 Mar 2021 08:39:48 +0800</pubDate></item><item><title>自身免疫疾病的生物学与临床研究进展</title><link>https://mp.weixin.qq.com/s/-OR5jXlg3u01eEqZFfebgw</link><description></description><content:encoded><![CDATA[自身免疫疾病的生物学与临床研究进展]]></content:encoded><pubDate>Mon, 22 Mar 2021 06:13:02 +0800</pubDate></item><item><title>15款产品蜂拥入临床，PROTAC能否重塑小分子荣光？</title><link>https://mp.weixin.qq.com/s/zfXTbEahmuvUe1px6pI5tA</link><description></description><content:encoded><![CDATA[15款产品蜂拥入临床，PROTAC能否重塑小分子荣光？]]></content:encoded><pubDate>Sun, 21 Mar 2021 10:07:19 +0800</pubDate></item><item><title>国际多中心临床试验的成功要素</title><link>https://mp.weixin.qq.com/s/o4M65-iO32iWKX_RQJQ72w</link><description></description><content:encoded><![CDATA[国际多中心临床试验的成功要素]]></content:encoded><pubDate>Sat, 20 Mar 2021 06:51:17 +0800</pubDate></item><item><title>临床方案设计与风险规避</title><link>https://mp.weixin.qq.com/s/_wD5KOrF2qCdbqCZbCWx_A</link><description></description><content:encoded><![CDATA[临床方案设计与风险规避]]></content:encoded><pubDate>Sat, 20 Mar 2021 06:51:17 +0800</pubDate></item><item><title>临床开发的重中之重—适应症的选择策略</title><link>https://mp.weixin.qq.com/s/XX2o3UKL1eeZVF9aQ2OA9g</link><description></description><content:encoded><![CDATA[临床开发的重中之重—适应症的选择策略]]></content:encoded><pubDate>Sat, 20 Mar 2021 06:51:17 +0800</pubDate></item><item><title>导致NDA撤回临床失败源头案例分享</title><link>https://mp.weixin.qq.com/s/8-mc8OH6Abb47dt8beI4tQ</link><description></description><content:encoded><![CDATA[导致NDA撤回临床失败源头案例分享]]></content:encoded><pubDate>Sat, 20 Mar 2021 06:51:17 +0800</pubDate></item><item><title>中国新药公司首席医学官（CMO）名录</title><link>https://mp.weixin.qq.com/s/watZsX-CriwiewuLsHsL0g</link><description></description><content:encoded><![CDATA[中国新药公司首席医学官（CMO）名录]]></content:encoded><pubDate>Sat, 20 Mar 2021 06:51:17 +0800</pubDate></item><item><title>创新药CMO为什么是“流动”的“火”</title><link>https://mp.weixin.qq.com/s/QLSvUK3DVLzRT5uBEbXwAA</link><description></description><content:encoded><![CDATA[创新药CMO为什么是“流动”的“火”]]></content:encoded><pubDate>Sat, 20 Mar 2021 06:51:17 +0800</pubDate></item></channel></rss>